Skip to content
10-Q

Quarterly Report

Damora Therapeutics, Inc. DMRA

0000950170-25-066884

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 5, 2025 1.32M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $11.94M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $14.18M
Current Liabilities Q1 2025 · Mar 31, 2025 $1.55M
Current Liabilities Q1 2025 · Dec 31, 2024 $1.2M
Total Liabilities Q1 2025 · Mar 31, 2025 $1.66M
Total Liabilities Q1 2025 · Dec 31, 2024 $1.3M
Current Assets Q1 2025 · Mar 31, 2025 $14.92M
Current Assets Q1 2025 · Dec 31, 2024 $16.84M
Total Assets Q1 2025 · Mar 31, 2025 $15.37M
Total Assets Q1 2025 · Dec 31, 2024 $17.13M
Shares Diluted restated Q1 2025 · Mar 31, 2024 1.08M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$5.94M
Stockholders Equity Q1 2025 · Mar 31, 2024 $28.16M
Stockholders Equity Q1 2025 · Dec 31, 2023 $32.33M
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$5.05
Eps Basic restated Q1 2025 · Mar 31, 2024 −$5.05
Sga Expense Q1 2025 · Mar 31, 2024 $3.28M
Rd Expense Q1 2025 · Mar 31, 2024 $2.46M
Net Income Q1 2025 · Mar 31, 2024 −$5.48M
Operating Income Q1 2025 · Mar 31, 2024 −$5.74M